ANI Snaps Up Novitium In Deal Worth Up To $210m
Pipeline Includes 505(b)(2) Products; Transaction Also Bolsters CDMO Business
ANI Pharmaceuticals has struck a deal worth up to $210m to acquire niche generics specialist Novitium Pharma, a move that the firm says will bring it a healthy pipeline of ANDAs and 505(b)(2) products as well as enhancing its CDMO business.
